Literature DB >> 32223438

Comparing the Benefit Of Novel Therapies Across Clinical Trials: Insights from the VICTORIA Trial.

Javed Butler1, Kevin J Anstrom2, Paul W Armstrong3.   

Abstract

Year:  2020        PMID： 32223438     DOI： 10.1161/CIRCULATIONAHA.120.047086

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  5 in total

1.  Novel sGC stimulator improves outcomes in patients with HFrEF.

Authors:  Karina Huynh
Journal:  Nat Rev Cardiol       Date:  2020-06       Impact factor: 32.419

2.  Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial.

Authors:  Ninian N Lang; Stephen J H Dobbin; Mark C Petrie
Journal:  Cardiovasc Res       Date:  2020-10-01       Impact factor: 10.787

Review 3.  Mechanisms and Models in Heart Failure: A Translational Approach.

Authors:  Douglas L Mann; G Michael Felker
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

Review 4.  Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction.

Authors:  Ammar G Chaudhary; Fadi M Alreefi; Mohammad A Aziz
Journal:  CJC Open       Date:  2021-02-01

5.  Real-world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction.

Authors:  Jaewon Oh; Chan Joo Lee; Jin Joo Park; Sang Eun Lee; Min-Seok Kim; Hyun-Jai Cho; Jin-Oh Choi; Hae-Young Lee; Kyung-Kuk Hwang; Kye Hun Kim; Byung-Su Yoo; Dong-Ju Choi; Sang Hong Baek; Eun-Seok Jeon; Jae-Joong Kim; Myeong-Chan Cho; Shung Chull Chae; Byung-Hee Oh; Seok-Min Kang
Journal:  ESC Heart Fail       Date:  2022-02-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.